Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18'25 years enrolled in a clinical trial

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2604-2611

  Zhao, Fang Hui ^a   Zhu, Feng Cai ^b   Chen, Wen ^a   Li, Juan ^c   Hu, Yue Mei ^b   Hong, Ying ^d   Zhang, Yi Ju ^b   Pan, Qin Jing ^a   Zhu, Jia Hong ^e   Zhang, Xun ^a   Chen, Yong ^f   Tang, Haiwen ^g   Zhang, Helen ^g   Durand, Christelle ^h   Datta, Sanjoy K ^h   Struyf, Frank ^h   Bi, Dan ^h  

^a CANCER HOSPITAL   (China)

^b JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^d THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^e Lianshui County Center for Disease Control and Prevention   (China)

^f CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^g GLAXOSMITHKLINE   (China)

^h GSK   (Belgium)

Author keywords

China; Human papillomavirus; Prevalence; Type distribution; Women

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; AGE; ANTIBODY TITER; ARTICLE; CHINA; CHINESE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 34; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 40; HUMAN PAPILLOMAVIRUS TYPE 43; HUMAN PAPILLOMAVIRUS TYPE 44; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 54; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN PAPILLOMAVIRUS TYPE 74; HUMAN TISSUE; IMMUNOGENICITY; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RURAL AREA; SEROLOGY; URBAN AREA; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; WART VIRUS; YOUNG ADULT; ADOLESCENT; CANCER STAGING; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; EPIDEMIOLOGY; FOLLOW UP; GENETICS; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; VAGINA SMEAR; VIROLOGY; WOMEN'S HEALTH;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CHINA; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DNA, VIRAL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; WOMEN'S HEALTH; YOUNG ADULT;

EID: 84921643937     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28896     Document Type: Article

References (32)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Available at http://globocan.iarc.fr. Retrieved 7 August 2013.
2. Shi JF, Canfell K, Lew JB, et al. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer 2012;130:641-52.
3. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184:9-13.
4. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9.
5. Zhu FC, Chen W, Hu YM, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomised controlled trial. Int J Cancer 2013;20:847-55.
6. Apgar BS, Zoschnick L, Wright TC, Jr. The 2001 Bethesda System terminology. Am Fam Physician 2003;68:1992-8.
7. van Doorn LJ, Molijn A, Kleter B, et al. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006;44:3292-8.
8. Dessy FJ, Giannini SL, Bougelet CA, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008;4: 425-34.
9. Li LK, Dai M, Clifford GM, et al. Human papillomavirus infection in Shenyang City, People's Republic of China: a population-based study. Br J Cancer 2006;95:1593-7.
10. Wu RF, Dai M, Qiao YL, et al. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer 2007; 121:1306-11.
11. Dai M, Bao YP, Li N, et al. Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer 2006;95:96-101.
12. Zhao R, Zhang WY, Wu MH, et al. Human papillomavirus infection in Beijing, People's Republic of China: a population-based study. Br J Cancer 2009;101:1635-40.
13. Perrons C, Kleter B, Jelley R, et al. Detection and genotyping of human papillomavirus DNA by SPF10 and MY09/11 primers in cervical cells taken from women attending a colposcopy clinic. J Med Virol 2002;67:246-52.
14. Molano M, Posso H, Weiderpass E, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002;87:324-33.
15. Matos E, Loria D, Amestoy GM, et al. Prevalence of human papillomavirus infection among women in Concordia, Argentina: a populationbased study. Sex Transm Dis 2003;30:593-9.
16. Ferreccio C, Prado RB, Luzoro AV, et al. Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev 2004;13:2271-6.
17. Franceschi S, Rajkumar R, Snijders PJ, et al. Papillomavirus infection in rural women in southern India. Br J Cancer 2005;92:601-6.
18. Thomas JO, Herrero R, Omigbodun AA, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004;90:638-45.
19. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008;26:4795-808.
20. Zhao FH, Lewkowitz AK, Hu SY, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer 2012; 131:2929-38.
21. Roset Bahmanyar E, Paavonen J, Naud P, et al. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol 2012;127:440-50.
22. Bao YP, Li N, Wang H, Qiao YL. Study on the distribution of human papillomavirus types in cervix among Chinese women: a meta-analysis. Zhonghua Liu Xing Bing Xue Za Zhi 2007;28:941-6.
23. Bao YP, Li N, Smith JS, et al. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. Int J STD AIDS 2008;19: 106-11.
24. Konno R, Shin HR, Kim YT, et al. Human papillomavirus infection and cervical cancer prevention in Japan and Korea. Vaccine 2008;26 Suppl 12:M30-42.
25. Miura S, Matsumoto K, Oki A, et al. Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer 2006;119: 2713-5.
26. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-9.
27. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131:2349-59.
28. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of typespecific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.
29. Chen W, Zhang X, Molijn A, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control 2009;20:1705-13.
30. Hu SY, Hong Y, Zhao FH, et al. Prevalence of HPV infection and cervical intraepithelial neoplasia and attitudes towards HPV vaccination among women aged 18-25 in Jiangsu province. Chin J Cancer Res 2011;23:25-32.
31. Zhao FH, Tiggelaar SM, Hu SY, et al. A multicenter survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vaccination in China. Cancer Epidemiol 2012;36:384-90.
32. van Doorn LJ, Quint W, Kleter B, et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol 2002;40:979-83.